BTK inhibitors are preferred when patients have TP53 alterations [2]. It is well known that LPL/WM is often associated with autoimmune disorders, including autoimmune hemolytic anemia (AIHA) or immune thrombocytopenia (ITP). The gene discussed is TP53; the disease is autoimmune hemolytic anemia.